PMI Marlboro Vista Sakura Blossom: New Cigarette in South Korea

Business by 2FIRSTS.ai
Jan.23.2024
PMI Marlboro Vista Sakura Blossom: New Cigarette in South Korea
Philip Morris Korea is set to release a new product, Marlboro Vista Sakura Mist, expanding their line to five options.

According to the latest report from South Korean media, Philip Morris Korea is set to launch a new product, the "Marlboro Vista Sakura Mist" cigarette, on the 25th. This is part of the Marlboro Vista Ultra Slim series and serves as a follow-up to the previously released "Marlboro Forest Mist" and "Marlboro Vista Tropical Breeze" products.

 

With the launch of this new product, the Marlboro Vista series has expanded to a total of five, offering consumers more choices. It is worth noting that this is the first 1mg ultrafine strip product in the Vista series, featuring a unique single-capsule form, providing consumers with a new smoking experience.

 

In addition to capsules and fresh filters, the new product also maintains the unique tobacco flavor of the Vistra series through scent boards and cigarette papers on the top of the product, effectively managing the taste experience of the hands and mouth.

 

Marlboro, a brand with a history of nearly 100 years since its first launch in 1924, has held the title of global best-selling brand for 50 consecutive years since 1972. It is present in more than 170 countries.

 

The "Malboro Vista Sakura Blossom Mist" will be available for sale nationwide in convenience stores and retail stores starting from January 25th, with a recommended retail price of 4500 Korean won.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Russian Nizhny Novgorod Deputies Propose Regional Power to Ban Vape Sales
Russian Nizhny Novgorod Deputies Propose Regional Power to Ban Vape Sales
The Nizhny Novgorod Legislative Assembly regional lawmakers have prepared a resolution proposing amendments to federal law that would grant Russian regions the authority to ban vape sales locally. The draft, developed by the assembly’s economic committee, was published this week.
Oct.24 by 2FIRSTS.ai
Australian Border Force Seizes 586M Cigarettes and 3M Vapes in Record First Quarter
Australian Border Force Seizes 586M Cigarettes and 3M Vapes in Record First Quarter
Australian Border Force (ABF), 586 million cigarettes and over 3 million vapes were seized at Australia’s international border in the first quarter of the 2024–25 financial year (July 1–September 30), marking a continued upward trend over the past two years. Enhanced intelligence and data-sharing have enabled ABF to target suspicious consignments more effectively across all entry points.
Oct.24 by 2FIRSTS.ai
NYS Youth Tobacco Use Down 29% Since 2022, Lowest Since 2000
NYS Youth Tobacco Use Down 29% Since 2022, Lowest Since 2000
According to the New York State Department of Health’s latest StatShot (Vol.17, #2025-1), high school tobacco product use in 2024 fell to 17.0%, the lowest rate since 2000, marking a 29% decline from 2022. E-cigarette use decreased from 18.7% to 13.1%, while cigarette use remained low at 2.4%.However, nicotine pouch use increased from 1.5% to 3.0%.
Oct.24 by 2FIRSTS.ai
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
California-based vape manufacturer Schwartz E-Liquid (USA Vape Lab) has sued the U.S. Food and Drug Administration (FDA) in federal court, alleging the agency unlawfully failed to issue a decision on its premarket application for flavored e-cigarette products for more than five years. The company is seeking a court order compelling the FDA to act within 90 days.
Nov.26 by 2FIRSTS.ai
COP11 Concludes with Major Decisions on Global Tobacco Control
COP11 Concludes with Major Decisions on Global Tobacco Control
The Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) concluded in Geneva on November 22, with 160 Parties adopting major decisions on tobacco and nicotine regulation, environmental protection, sustainable financing, and tobacco industry liability. A landmark decision mandates a complete ban on the use and sale of tobacco and all novel nicotine products across all UN premises worldwide.
Nov.24 by 2FIRSTS.ai